Our science
Building on our foundational expertise in carbohydrate chemistry and cell cycle biology, we develop innovative treatments for unmet patient needs with a focus on iron metabolism and blood-related disorders.
What is chemotherapy-induced myelosuppression (CIM)?
Chemotherapy-induced myelosuppression (CIM) is a serious and common complication of chemotherapy that significantly affects patients with extensive-stage small cell lung cancer (ES-SCLC). As chemotherapy disrupts and kills rapidly dividing cancer cells, it also impairs the bone marrow’s ability to produce critical blood components—white blood cells, red blood cells, and platelets—leading to neutropenia, anemia, and thrombocytopenia.
Goldschmidt. ES-SCLC CIM Burden Community: Blue Ridge Cancer Center, US Oncology Network. 2022.
Epstein. ES-SCLC Retrospective Real-World Evidence Communication: Providence St. John Health. January 2022.
Clinical consequences of CIM
The clinical consequences of CIM are substantial. Patients may experience fatigue, dizziness, and shortness of breath (anemia); increased risk of infections and fever (neutropenia); and easy bruising or bleeding (thrombocytopenia). These symptoms can severely impact a patient’s quality of life, often leading to treatment delays, dose reductions, or hospitalizations.
For patients with ES-SCLC, who often require aggressive and sustained chemotherapy, CIM presents a significant barrier to maintaining treatment intensity and optimizing outcomes.
Goldschmidt. ES-SCLC CIM Burden Community: Blue Ridge Cancer Center, US Oncology Network. 2022.
Epstein. ES-SCLC Retrospective Real-World Evidence Communication: Providence St. John Health. January 2022.
Effective management of CIM
Effective management of CIM is essential not only for supporting patient well-being but also for enabling clinicians to deliver uninterrupted cancer care.
Proactively protecting the bone marrow can help maintain dose intensity, reduce complications, and support patients in completing their prescribed therapy. In the management of ES-SCLC, where every treatment cycle matters, mitigating CIM is not only a clinical priority but a critical step in delivering optimal care.
Goldschmidt. ES-SCLC CIM Burden Community: Blue Ridge Cancer Center, US Oncology Network. 2022.
Epstein. ES-SCLC Retrospective Real-World Evidence Communication: Providence St. John Health. January 2022.
Critical need to address CIM
At Pharmacosmos, we recognize the critical need to address CIM in the oncology setting. By advancing innovative approaches to protect bone marrow and reduce the burden of CIM, we are committed to improving the treatment experience and outcomes for patients facing the challenges of extensive-stage small cell lung cancer.
Pharmacosmos Therapeutics Inc is...
A leader in providing innovative treatments for unmet patient needs, with a focus on iron metabolism and blood related disorders.
